Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas.
To predict the prognosis of neuroblastoma patients and choose a better therapeutic protocol, we developed a cDNA microarray carrying 5340 genes obtained from primary neuroblastomas and examined 136 tumor samples. We made a probabilistic output statistical classifier that provided a high accuracy in prognosis prediction (89% at 5 years) and a highly reliable method to validate it. Kaplan-Meier analysis indicated that the patients in an intermediate group defined by existing markers are divided by microarray into two further groups with 5 year survivals for 36% and 89% of patients (p < 10(-4)), i.e., with unfavorably and favorably predicted neuroblastomas, respectively. According to these results, we developed a gene subset chip for a clinical tool, for which our classifier exhibited 88% prediction accuracy.
Ohira
Miki
M
Division of Biochemistry, Chiba Cancer Center Research Institute, Chiba 260-8717, Japan.
Oba
Shigeyuki
S
Nakamura
Yohko
Y
Isogai
Eriko
E
Kaneko
Setsuko
S
Nakagawa
Atsuko
A
Hirata
Takahiro
T
Kubo
Hiroyuki
H
Goto
Takeshi
T
Yamada
Saichi
S
Yoshida
Yasuko
Y
Fuchioka
Misa
M
Ishii
Shin
S
Nakagawara
Akira
A
D000465:Algorithms; D001185:Artificial Intelligence; D020869:Gene Expression Profiling / Q000379:methods* / Q000706:statistics & numerical data; D006801:Humans; D015233:Models, Statistical; D009367:Neoplasm Staging; D009369:Neoplasms / Q000175:diagnosis / Q000235:genetics; D009447:Neuroblastoma / Q000145:classification / Q000175:diagnosis* / Q000235:genetics; D020411:Oligonucleotide Array Sequence Analysis / Q000379:methods* / Q000706:statistics & numerical data; D011379:Prognosis; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D016019:Survival Analysis